JPWO2019199972A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019199972A5 JPWO2019199972A5 JP2020555883A JP2020555883A JPWO2019199972A5 JP WO2019199972 A5 JPWO2019199972 A5 JP WO2019199972A5 JP 2020555883 A JP2020555883 A JP 2020555883A JP 2020555883 A JP2020555883 A JP 2020555883A JP WO2019199972 A5 JPWO2019199972 A5 JP WO2019199972A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- solvate
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 174
- 150000003839 salts Chemical class 0.000 claims description 137
- 239000012453 solvate Substances 0.000 claims description 135
- -1 hydroxy, amino, methoxy Chemical group 0.000 claims description 122
- 229910052739 hydrogen Inorganic materials 0.000 claims description 67
- 239000001257 hydrogen Substances 0.000 claims description 49
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 32
- 229910052805 deuterium Inorganic materials 0.000 claims description 28
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 25
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 125000001072 heteroaryl group Chemical group 0.000 claims description 22
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims description 21
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000006747 (C2-C10) heterocycloalkyl group Chemical group 0.000 claims 1
- 125000004171 alkoxy aryl group Chemical group 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 1
- 229940126523 co-drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108010008599 Forkhead Box Protein M1 Proteins 0.000 description 34
- 102000007237 Forkhead Box Protein M1 Human genes 0.000 description 33
- 150000002431 hydrogen Chemical class 0.000 description 31
- 238000000034 method Methods 0.000 description 29
- 108020004999 messenger RNA Proteins 0.000 description 26
- 102000006479 Heterogeneous-Nuclear Ribonucleoproteins Human genes 0.000 description 14
- 108010019372 Heterogeneous-Nuclear Ribonucleoproteins Proteins 0.000 description 14
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 14
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 13
- 125000003282 alkyl amino group Chemical group 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 108020004688 Small Nuclear RNA Proteins 0.000 description 5
- 102000039471 Small Nuclear RNA Human genes 0.000 description 5
- 229940088644 n,n-dimethylacrylamide Drugs 0.000 description 5
- 125000003566 oxetanyl group Chemical group 0.000 description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 4
- 102100030056 Splicing factor 1 Human genes 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 125000005504 styryl group Chemical group 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- FYGHWRRMUHLVJV-XYOKQWHBSA-N (E)-3-[3-hydroxy-4-[6-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl]phenyl]-N-methylprop-2-enamide Chemical compound CC1(CC(CC(N1)(C)C)N(C)C2=NN=C(C=C2)C3=C(C=C(C=C3)/C=C/C(=O)NC)O)C FYGHWRRMUHLVJV-XYOKQWHBSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108010029782 Nuclear Cap-Binding Protein Complex Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108020005067 RNA Splice Sites Proteins 0.000 description 2
- 108010003165 Small Nuclear Ribonucleoproteins Proteins 0.000 description 2
- 102000004598 Small Nuclear Ribonucleoproteins Human genes 0.000 description 2
- 101710153291 Splicing factor 1 Proteins 0.000 description 2
- 108091026838 U1 spliceosomal RNA Proteins 0.000 description 2
- 102000018686 U4-U6 Small Nuclear Ribonucleoprotein Human genes 0.000 description 2
- 108010091808 U4-U6 Small Nuclear Ribonucleoprotein Proteins 0.000 description 2
- 108091026837 U5 spliceosomal RNA Proteins 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 125000004474 heteroalkylene group Chemical group 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000003584 silencer Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- ULBZXAWQUJAUEH-MDZDMXLPSA-N (E)-2-[2-chloro-5-hydroxy-4-[6-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl]phenyl]-N-methylethenesulfonamide Chemical compound ClC1=C(C=C(C(=C1)C=1N=NC(=CC=1)N(C1CC(NC(C1)(C)C)(C)C)C)O)/C=C/S(=O)(=O)NC ULBZXAWQUJAUEH-MDZDMXLPSA-N 0.000 description 1
- NJTYPBMWGCXPES-VAWYXSNFSA-N (E)-2-[3-hydroxy-4-[6-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl]phenyl]-N-methylethenesulfonamide Chemical compound CC1(CC(CC(N1)(C)C)N(C)C2=NN=C(C=C2)C3=C(C=C(C=C3)/C=C/S(=O)(=O)NC)O)C NJTYPBMWGCXPES-VAWYXSNFSA-N 0.000 description 1
- KPWUAWWTZWKZTH-JXMROGBWSA-N (E)-3-[2-fluoro-5-hydroxy-4-[6-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl]phenyl]-N-methylprop-2-enamide Chemical compound FC1=C(C=C(C(=C1)C=1N=NC(=CC=1)N(C1CC(NC(C1)(C)C)(C)C)C)O)/C=C/C(=O)NC KPWUAWWTZWKZTH-JXMROGBWSA-N 0.000 description 1
- BBLYBJYBOVPGEH-FOWTUZBSSA-N (E)-3-[3-hydroxy-4-[6-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl]phenyl]-N-methylbut-2-enamide Chemical compound C/C(=C\C(=O)NC)/C1=CC(=C(C=C1)C2=NN=C(C=C2)N(C)C3CC(NC(C3)(C)C)(C)C)O BBLYBJYBOVPGEH-FOWTUZBSSA-N 0.000 description 1
- INTDSWCQTHYXFR-GORDUTHDSA-N (E)-3-[4-[6-(4-aminopiperidin-1-yl)pyridazin-3-yl]-2-fluoro-5-hydroxyphenyl]-N-methylprop-2-enamide Chemical compound NC1CCN(CC1)C1=CC=C(N=N1)C1=CC(=C(C=C1O)/C=C/C(=O)NC)F INTDSWCQTHYXFR-GORDUTHDSA-N 0.000 description 1
- QOEHGYUTXVZAAK-XVNBXDOJSA-N (E)-3-[4-[6-(4-aminopiperidin-1-yl)pyridazin-3-yl]-3-hydroxyphenyl]-N-methylprop-2-enamide Chemical compound CNC(=O)/C=C/C1=CC(=C(C=C1)C2=NN=C(C=C2)N3CCC(CC3)N)O QOEHGYUTXVZAAK-XVNBXDOJSA-N 0.000 description 1
- QCLMDGFJOYGZNZ-YBGBEFGJSA-N (E)-3-[4-[6-[(3aS,6aR)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrol-5-yl]pyridazin-3-yl]-2-fluoro-5-hydroxyphenyl]-N-methylprop-2-enamide Chemical compound FC1=C(C=C(C(=C1)C=1N=NC(=CC=1)N1C[C@@H]2CNC[C@@H]2C1)O)/C=C/C(=O)NC QCLMDGFJOYGZNZ-YBGBEFGJSA-N 0.000 description 1
- AKWRAAXSKYYTMH-JRLNFQKPSA-N (E)-3-[4-[6-[(3aS,6aR)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrol-5-yl]pyridazin-3-yl]-3-hydroxyphenyl]-N-methylprop-2-enamide Chemical compound C1N(C[C@@H]2[C@H]1CNC2)C1=CC=C(N=N1)C1=C(C=C(C=C1)/C=C/C(=O)NC)O AKWRAAXSKYYTMH-JRLNFQKPSA-N 0.000 description 1
- HAWSJJSOBNPTAN-BRLZAQAVSA-N (E)-3-[4-[6-[[(1R,4R,5S)-2-azabicyclo[2.2.1]heptan-5-yl]-methylamino]pyridazin-3-yl]-3-hydroxyphenyl]-N-methylprop-2-enamide Chemical compound CNC(=O)/C=C/C1=CC(=C(C=C1)C2=NN=C(C=C2)N(C)[C@H]3C[C@H]4C[C@@H]3CN4)O HAWSJJSOBNPTAN-BRLZAQAVSA-N 0.000 description 1
- PQASPYKXIZQBGT-WPBALSLYSA-N (E)-3-[4-[6-[[(1R,4R,5S)-2-azabicyclo[2.2.1]heptan-5-yl]oxy]pyridazin-3-yl]-3-hydroxyphenyl]-N-methylprop-2-enamide Chemical compound CNC(=O)/C=C/C1=CC(=C(C=C1)C2=NN=C(C=C2)O[C@H]3C[C@H]4C[C@@H]3CN4)O PQASPYKXIZQBGT-WPBALSLYSA-N 0.000 description 1
- DUOQRNNCTGUODR-WPBALSLYSA-N (E)-3-[4-[6-[[(1R,4R,5S)-2-azabicyclo[2.2.1]heptan-5-yl]sulfanyl]pyridazin-3-yl]-3-hydroxyphenyl]-N-methylprop-2-enamide Chemical compound CNC(=O)/C=C/C1=CC(=C(C=C1)C2=NN=C(C=C2)S[C@H]3C[C@H]4C[C@@H]3CN4)O DUOQRNNCTGUODR-WPBALSLYSA-N 0.000 description 1
- YUGPYBHDSBSUNE-BIJNAOSNSA-N (E)-3-[4-[6-[[(1R,4R,5S)-2-azabicyclo[2.2.2]octan-5-yl]-methylamino]pyridazin-3-yl]-3-hydroxyphenyl]-N-methylprop-2-enamide Chemical compound [C@H]12NC[C@H]([C@H](C1)N(C1=CC=C(N=N1)C1=C(C=C(C=C1)/C=C/C(=O)NC)O)C)CC2 YUGPYBHDSBSUNE-BIJNAOSNSA-N 0.000 description 1
- HXQGGANEDKIGJL-NZVUABHMSA-N (E)-3-[4-[6-[[(1R,4R,5S)-2-azabicyclo[2.2.2]octan-5-yl]oxy]pyridazin-3-yl]-3-hydroxyphenyl]-N-methylprop-2-enamide Chemical compound [C@H]12NC[C@H]([C@H](C1)OC1=CC=C(N=N1)C1=C(C=C(C=C1)/C=C/C(=O)NC)O)CC2 HXQGGANEDKIGJL-NZVUABHMSA-N 0.000 description 1
- HFBSGUOVEUADAF-NZVUABHMSA-N (E)-3-[4-[6-[[(1R,4R,5S)-2-azabicyclo[2.2.2]octan-5-yl]sulfanyl]pyridazin-3-yl]-3-hydroxyphenyl]-N-methylprop-2-enamide Chemical compound [C@H]12NC[C@H]([C@H](C1)SC1=CC=C(N=N1)C1=C(C=C(C=C1)/C=C/C(=O)NC)O)CC2 HFBSGUOVEUADAF-NZVUABHMSA-N 0.000 description 1
- HAWSJJSOBNPTAN-DPDULKMESA-N (E)-3-[4-[6-[[(1S,4S,5R)-2-azabicyclo[2.2.1]heptan-5-yl]-methylamino]pyridazin-3-yl]-3-hydroxyphenyl]-N-methylprop-2-enamide Chemical compound CNC(=O)/C=C/C1=CC(=C(C=C1)C2=NN=C(C=C2)N(C)[C@@H]3C[C@@H]4C[C@H]3CN4)O HAWSJJSOBNPTAN-DPDULKMESA-N 0.000 description 1
- PQASPYKXIZQBGT-XIVUFIJJSA-N (E)-3-[4-[6-[[(1S,4S,5R)-2-azabicyclo[2.2.1]heptan-5-yl]oxy]pyridazin-3-yl]-3-hydroxyphenyl]-N-methylprop-2-enamide Chemical compound CNC(=O)/C=C/C1=CC(=C(C=C1)C2=NN=C(C=C2)O[C@@H]3C[C@@H]4C[C@H]3CN4)O PQASPYKXIZQBGT-XIVUFIJJSA-N 0.000 description 1
- DUOQRNNCTGUODR-XIVUFIJJSA-N (E)-3-[4-[6-[[(1S,4S,5R)-2-azabicyclo[2.2.1]heptan-5-yl]sulfanyl]pyridazin-3-yl]-3-hydroxyphenyl]-N-methylprop-2-enamide Chemical compound CNC(=O)/C=C/C1=CC(=C(C=C1)C2=NN=C(C=C2)S[C@@H]3C[C@@H]4C[C@H]3CN4)O DUOQRNNCTGUODR-XIVUFIJJSA-N 0.000 description 1
- YUGPYBHDSBSUNE-XWLVFEQFSA-N (E)-3-[4-[6-[[(1S,4S,5R)-2-azabicyclo[2.2.2]octan-5-yl]-methylamino]pyridazin-3-yl]-3-hydroxyphenyl]-N-methylprop-2-enamide Chemical compound CNC(=O)/C=C/C1=CC(=C(C=C1)C2=NN=C(C=C2)N(C)[C@@H]3C[C@@H]4CC[C@H]3CN4)O YUGPYBHDSBSUNE-XWLVFEQFSA-N 0.000 description 1
- HXQGGANEDKIGJL-BSKNGRPTSA-N (E)-3-[4-[6-[[(1S,4S,5R)-2-azabicyclo[2.2.2]octan-5-yl]oxy]pyridazin-3-yl]-3-hydroxyphenyl]-N-methylprop-2-enamide Chemical compound CNC(=O)/C=C/C1=CC(=C(C=C1)C2=NN=C(C=C2)O[C@@H]3C[C@@H]4CC[C@H]3CN4)O HXQGGANEDKIGJL-BSKNGRPTSA-N 0.000 description 1
- HFBSGUOVEUADAF-BSKNGRPTSA-N (E)-3-[4-[6-[[(1S,4S,5R)-2-azabicyclo[2.2.2]octan-5-yl]sulfanyl]pyridazin-3-yl]-3-hydroxyphenyl]-N-methylprop-2-enamide Chemical compound CNC(=O)/C=C/C1=CC(=C(C=C1)C2=NN=C(C=C2)S[C@@H]3C[C@@H]4CC[C@H]3CN4)O HFBSGUOVEUADAF-BSKNGRPTSA-N 0.000 description 1
- LCRAVTDOXVUHJL-MDZDMXLPSA-N 4-fluoro-5-[(E)-2-methylsulfonylethenyl]-2-[6-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl]phenol Chemical compound FC1=CC(=C(C=C1\C=C\S(=O)(=O)C)O)C=1N=NC(=CC=1)N(C1CC(NC(C1)(C)C)(C)C)C LCRAVTDOXVUHJL-MDZDMXLPSA-N 0.000 description 1
- PNIKKYBZSGOJPW-VAWYXSNFSA-N 5-[(E)-2-methylsulfonylethenyl]-2-[6-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl]phenol Chemical compound CN(C1=CC=C(N=N1)C1=C(C=C(C=C1)\C=C\S(=O)(=O)C)O)C1CC(NC(C1)(C)C)(C)C PNIKKYBZSGOJPW-VAWYXSNFSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 101100478296 Arabidopsis thaliana SR45A gene Proteins 0.000 description 1
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 description 1
- 102100034799 CCAAT/enhancer-binding protein delta Human genes 0.000 description 1
- SXFCVTWQYKWJAG-GMXVVIOVSA-N C[C@@](CC1)(C2)N[C@@H]1C[C@@H]2N(C)C1=CC=CN=N1 Chemical compound C[C@@](CC1)(C2)N[C@@H]1C[C@@H]2N(C)C1=CC=CN=N1 SXFCVTWQYKWJAG-GMXVVIOVSA-N 0.000 description 1
- 101710141326 Heterogeneous nuclear ribonucleoprotein C Proteins 0.000 description 1
- 102100028909 Heterogeneous nuclear ribonucleoprotein K Human genes 0.000 description 1
- 102100024002 Heterogeneous nuclear ribonucleoprotein U Human genes 0.000 description 1
- 102000004638 Heterogeneous-Nuclear Ribonucleoprotein Group M Human genes 0.000 description 1
- 108010042923 Heterogeneous-Nuclear Ribonucleoprotein Group M Proteins 0.000 description 1
- 108010084680 Heterogeneous-Nuclear Ribonucleoprotein K Proteins 0.000 description 1
- 108010085697 Heterogeneous-Nuclear Ribonucleoprotein U Proteins 0.000 description 1
- 101000945965 Homo sapiens CCAAT/enhancer-binding protein delta Proteins 0.000 description 1
- 101000907578 Homo sapiens Forkhead box protein M1 Proteins 0.000 description 1
- 101100340769 Homo sapiens ILF2 gene Proteins 0.000 description 1
- 101001033293 Homo sapiens Interleukin enhancer-binding factor 3 Proteins 0.000 description 1
- 101001135406 Homo sapiens Polypyrimidine tract-binding protein 2 Proteins 0.000 description 1
- 101001125496 Homo sapiens Pre-mRNA-processing factor 19 Proteins 0.000 description 1
- 101001076721 Homo sapiens RNA-binding protein 38 Proteins 0.000 description 1
- 101000829212 Homo sapiens Serine/arginine repetitive matrix protein 2 Proteins 0.000 description 1
- 101000643391 Homo sapiens Serine/arginine-rich splicing factor 11 Proteins 0.000 description 1
- 101000587430 Homo sapiens Serine/arginine-rich splicing factor 2 Proteins 0.000 description 1
- 101000587434 Homo sapiens Serine/arginine-rich splicing factor 3 Proteins 0.000 description 1
- 101000700734 Homo sapiens Serine/arginine-rich splicing factor 9 Proteins 0.000 description 1
- 101000808799 Homo sapiens Splicing factor U2AF 35 kDa subunit Proteins 0.000 description 1
- 101000679343 Homo sapiens Transformer-2 protein homolog beta Proteins 0.000 description 1
- 101000658084 Homo sapiens U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2 Proteins 0.000 description 1
- 101000823796 Homo sapiens Y-box-binding protein 1 Proteins 0.000 description 1
- 102100039060 Interleukin enhancer-binding factor 2 Human genes 0.000 description 1
- 102100039062 Interleukin enhancer-binding factor 3 Human genes 0.000 description 1
- 102100023408 KH domain-containing, RNA-binding, signal transduction-associated protein 1 Human genes 0.000 description 1
- 101710094958 KH domain-containing, RNA-binding, signal transduction-associated protein 1 Proteins 0.000 description 1
- 108700021638 Neuro-Oncological Ventral Antigen Proteins 0.000 description 1
- 101100110007 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) asd-1 gene Proteins 0.000 description 1
- 101100281518 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) fox-2 gene Proteins 0.000 description 1
- 102000001745 Nuclear Cap-Binding Protein Complex Human genes 0.000 description 1
- 108700031302 Nuclear Factor 45 Proteins 0.000 description 1
- 102100032342 Nuclear cap-binding protein subunit 2 Human genes 0.000 description 1
- 102100033280 Polypyrimidine tract-binding protein 2 Human genes 0.000 description 1
- 102100029522 Pre-mRNA-processing factor 19 Human genes 0.000 description 1
- 102100025859 RNA-binding protein 38 Human genes 0.000 description 1
- 101100473045 Rattus norvegicus Hnrnpa2b1 gene Proteins 0.000 description 1
- 102100023657 Serine/arginine repetitive matrix protein 2 Human genes 0.000 description 1
- 102100035719 Serine/arginine-rich splicing factor 11 Human genes 0.000 description 1
- 102100029666 Serine/arginine-rich splicing factor 2 Human genes 0.000 description 1
- 102100029665 Serine/arginine-rich splicing factor 3 Human genes 0.000 description 1
- 102100029288 Serine/arginine-rich splicing factor 9 Human genes 0.000 description 1
- 102100038501 Splicing factor U2AF 35 kDa subunit Human genes 0.000 description 1
- 102100022572 Transformer-2 protein homolog beta Human genes 0.000 description 1
- 108010091281 U1 Small Nuclear Ribonucleoprotein Proteins 0.000 description 1
- 102000018165 U1 Small Nuclear Ribonucleoprotein Human genes 0.000 description 1
- 102100035136 U1 small nuclear ribonucleoprotein C Human genes 0.000 description 1
- 101710106596 U1 small nuclear ribonucleoprotein C Proteins 0.000 description 1
- 101150056683 U11 gene Proteins 0.000 description 1
- 108091026904 U11 spliceosomal RNA Proteins 0.000 description 1
- 108091026909 U12 minor spliceosomal RNA Proteins 0.000 description 1
- 108010072724 U2 Small Nuclear Ribonucleoprotein Proteins 0.000 description 1
- 102000006986 U2 Small Nuclear Ribonucleoprotein Human genes 0.000 description 1
- 102100035036 U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2 Human genes 0.000 description 1
- 108091026828 U2 spliceosomal RNA Proteins 0.000 description 1
- 108091026831 U4 spliceosomal RNA Proteins 0.000 description 1
- 108010086857 U5 Small Nuclear Ribonucleoprotein Proteins 0.000 description 1
- 102000006837 U5 Small Nuclear Ribonucleoprotein Human genes 0.000 description 1
- 108091026822 U6 spliceosomal RNA Proteins 0.000 description 1
- 101150105896 Uts2b gene Proteins 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 101150058668 tra2 gene Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862655431P | 2018-04-10 | 2018-04-10 | |
| US62/655,431 | 2018-04-10 | ||
| PCT/US2019/026788 WO2019199972A1 (en) | 2018-04-10 | 2019-04-10 | Compounds for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521200A JP2021521200A (ja) | 2021-08-26 |
| JPWO2019199972A5 true JPWO2019199972A5 (https=) | 2022-04-19 |
| JP2021521200A5 JP2021521200A5 (https=) | 2022-04-19 |
Family
ID=68164559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555883A Pending JP2021521200A (ja) | 2018-04-10 | 2019-04-10 | 癌の処置のための化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11530207B2 (https=) |
| EP (1) | EP3781564B1 (https=) |
| JP (1) | JP2021521200A (https=) |
| KR (1) | KR20200142039A (https=) |
| CN (1) | CN112272666A (https=) |
| WO (1) | WO2019199972A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7312749B2 (ja) | 2017-08-04 | 2023-07-21 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングをモジュレートする方法および組成物 |
| JP2022519637A (ja) * | 2019-02-04 | 2022-03-24 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| JP7551629B2 (ja) | 2019-02-05 | 2024-09-17 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| WO2020163405A1 (en) * | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| WO2020163401A1 (en) * | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| WO2020163406A1 (en) * | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| JP7603595B2 (ja) * | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| JP7603594B2 (ja) * | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| UY38687A (es) | 2019-05-17 | 2023-05-15 | Novartis Ag | Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso |
| WO2021071981A1 (en) * | 2019-10-08 | 2021-04-15 | Skyhawk Therapeutics, Inc. | Compounds for modulating splicing |
| WO2021071984A1 (en) * | 2019-10-08 | 2021-04-15 | Skyhawk Therapeutics, Inc. | Compounds for modulating splicing |
| WO2021071983A1 (en) * | 2019-10-08 | 2021-04-15 | Skyhawk Therapeutics, Inc. | Compounds for modulating splicing |
| CN115485025A (zh) | 2020-02-28 | 2022-12-16 | 雷密克斯医疗公司 | 用于调节剪接的化合物和方法 |
| WO2021174176A1 (en) | 2020-02-28 | 2021-09-02 | Remix Therapeutics Inc. | Pyridazine dervatives for modulating nucleic acid splicing |
| WO2021174174A1 (en) | 2020-02-28 | 2021-09-02 | Remix Therapeutics Inc. | Thiophenyl derivatives useful for modulating nucleic acid splicing |
| MX2022010681A (es) | 2020-02-28 | 2023-03-21 | Remix Therapeutics Inc | Compuestos y metodos para modular el empalme. |
| MX2022012678A (es) | 2020-04-08 | 2023-01-11 | Remix Therapeutics Inc | Compuestos y metodos para modular el corte y empalme. |
| WO2021207530A1 (en) | 2020-04-08 | 2021-10-14 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| TW202216710A (zh) | 2020-07-02 | 2022-05-01 | 美商雷密克斯醫療公司 | 調節剪接之化合物及方法 |
| CN116940578A (zh) * | 2020-07-02 | 2023-10-24 | 雷密克斯医疗公司 | 5-[5-(哌啶-4-基)噻吩并[3,2-c]吡唑-2-基]吲唑衍生物和相关化合物作为调节剂用于剪接核酸和治疗增殖性疾病 |
| MX2023000167A (es) * | 2020-07-02 | 2023-05-03 | Remix Therapeutics Inc | Derivados de 5-[5-(piperidin-4-il)tieno[3,2-c]pirazol-2-il]indazol y compuestos relacionados como moduladores para el corte y empalme de ácidos nucleicos y para el tratamiento de enfermedades proliferativas. |
| MX2023001558A (es) * | 2020-08-05 | 2023-04-26 | Skyhawk Therapeutics Inc | Composiciones para modular el corte y empalme. |
| WO2022060951A1 (en) * | 2020-09-16 | 2022-03-24 | Skyhawk Therapeutics, Inc. | Compositions for modulating splicing |
| GB2603454A (en) * | 2020-12-09 | 2022-08-10 | Ucl Business Ltd | Novel therapeutics for the treatment of neurodegenerative disorders |
| CN112662780A (zh) * | 2021-01-29 | 2021-04-16 | 复旦大学附属中山医院 | 检测hnrnpm表达的试剂在制备诊断和/或预后判断肝癌中的应用及药物组合物 |
| WO2023034812A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| US20240400584A1 (en) | 2021-08-30 | 2024-12-05 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| US20240368163A1 (en) | 2021-08-30 | 2024-11-07 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| US20250333397A1 (en) | 2021-08-30 | 2025-10-30 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| CA3230256A1 (en) | 2021-08-30 | 2023-03-09 | Dominic Reynolds | Compounds and methods for modulating splicing |
| IL312078A (en) | 2021-10-13 | 2024-06-01 | Remix Therapeutics Inc | Compounds and methods for modulating nucleic acid splicing |
| TW202330552A (zh) | 2021-10-13 | 2023-08-01 | 美商雷密克斯醫療公司 | 調節剪接之化合物及方法 |
| WO2023133217A1 (en) | 2022-01-05 | 2023-07-13 | Remix Therapeutics Inc. | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| WO2023133229A2 (en) | 2022-01-05 | 2023-07-13 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| TW202346305A (zh) | 2022-01-05 | 2023-12-01 | 美商雷密克斯醫療公司 | 用於調節剪切之化合物及方法 |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901464A (fr) | 1943-01-23 | 1945-07-27 | Boehringer & Soehne Gmbh | Procédé d'obtention de vanilline |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US7189737B2 (en) | 1991-08-09 | 2007-03-13 | Research Triangle Institute | Cocaine receptor binding ligands |
| US5128118A (en) * | 1990-08-09 | 1992-07-07 | Research Triangle Institute | Cocaine receptor binding ligands |
| GB0311201D0 (en) * | 2003-05-15 | 2003-06-18 | Merck Sharp & Dohme | Therapeutic agents |
| US7399765B2 (en) * | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
| EP1805183B1 (en) | 2004-10-20 | 2010-12-29 | NeuroSearch A/S | Novel diazabicyclic aryl derivatives and their medical use |
| US7834178B2 (en) | 2006-03-01 | 2010-11-16 | Bristol-Myers Squibb Company | Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors |
| FR2926297B1 (fr) * | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage. |
| ES2464102T3 (es) * | 2008-03-27 | 2014-05-30 | Grünenthal GmbH | Derivados de 4-aminociclohexano sustituidos |
| US8729263B2 (en) * | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| EP3035935B1 (en) | 2013-08-19 | 2020-03-11 | F. Hoffmann-La Roche AG | Compounds for use in the prophylaxis and treatment of cancer |
| EP3256126B1 (en) * | 2015-02-09 | 2024-03-27 | F. Hoffmann-La Roche AG | Compounds for the treatment of cancer |
| EP3053577A1 (en) * | 2015-02-09 | 2016-08-10 | F. Hoffmann-La Roche AG | Compounds for the treatment of cancer |
| US10668171B2 (en) * | 2015-05-30 | 2020-06-02 | Ptc Therapeutics, Inc. | Methods for modulating RNA splicing |
| EA201800367A1 (ru) * | 2015-12-10 | 2019-02-28 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы лечения болезни хантингтона |
| JP7312749B2 (ja) | 2017-08-04 | 2023-07-21 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングをモジュレートする方法および組成物 |
| US20230152257A1 (en) | 2017-09-25 | 2023-05-18 | Skyhawk Therapeutics, Inc. | Methods and compositions for screening and identification of splicing |
-
2019
- 2019-04-10 JP JP2020555883A patent/JP2021521200A/ja active Pending
- 2019-04-10 KR KR1020207032337A patent/KR20200142039A/ko not_active Ceased
- 2019-04-10 EP EP19785483.9A patent/EP3781564B1/en active Active
- 2019-04-10 WO PCT/US2019/026788 patent/WO2019199972A1/en not_active Ceased
- 2019-04-10 US US17/046,245 patent/US11530207B2/en active Active
- 2019-04-10 CN CN201980037767.2A patent/CN112272666A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019199972A5 (https=) | ||
| JP2021521200A5 (https=) | ||
| JP2020537657A5 (https=) | ||
| JP2020528889A5 (https=) | ||
| CN105384687B (zh) | 喹啉酮类化合物及其在药物中应用 | |
| CN108727378A (zh) | 新型异喹啉类化合物及其医药用途 | |
| JP2010505930A5 (https=) | ||
| WO2019129216A1 (zh) | 一种吡啶基咪唑并苯并二氮杂卓丙酸酯化合物及其合成和应用 | |
| AU2008255815B2 (en) | Tetrahydroisoquinolin-1-one derivative or salt thereof | |
| KR20220143775A (ko) | 치환된 피리다진온류 화합물과 그 용도 | |
| WO2019137201A1 (zh) | 杂芳基并四氢吡啶类化合物、其制备方法、药物组合物及应用 | |
| CN112513006A (zh) | 用于合成(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸的工艺 | |
| CN115066425A (zh) | Jak抑制剂在制备治疗jak激酶相关疾病药物中的应用 | |
| JP2012501308A (ja) | ピラゾリルピリミジン誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用 | |
| JP2000516257A (ja) | タキキニンアンタゴニスト | |
| JP2024505912A (ja) | 連環を含むｔｙｋ２阻害剤化合物 | |
| JP7381136B2 (ja) | 高血圧症及び／又は線維症を処置するための組成物 | |
| JP2002528541A (ja) | Ｔｎｆおよびｐｄｅ−ｉｖ阻害活性を有する複素環式化合物のｎ−オキシド | |
| JPWO2020102100A5 (https=) | ||
| TW202021965A (zh) | 吡咯并[1,2-b]嗒衍生物 | |
| JP2024523558A (ja) | 脳腫瘍の治療における使用のためのｅｇｆｒの（１ｈ－ピロロ［２，３－ｂ］ピリジン－１－イル）ピリミジン－２－イル－アミノ－フェニル－アクリルアミド阻害剤 | |
| WO2022166991A1 (zh) | 吲哚啉类化合物 | |
| WO2022033303A1 (zh) | 苄胺类衍生物及其制备方法与用途 | |
| WO2019233366A1 (zh) | 选择性a 2a受体拮抗剂 | |
| JPWO2023091554A5 (https=) |